DC
VYGR icon

Diametric Capital’s Voyager Therapeutics VYGR Stock Holding History

Diametric Capital’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-12,527
Closed -$96.6K – 470
2023
Q1 		$96.6K Buy
+12,527
New +$99.6K 0.05% 268

Other funds holding VYGR

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Diametric Capital's VYGR Position: Q2 2023 in Review

Diametric Capital sold out of Voyager Therapeutics (VYGR) in Q2 2023, closing a stake of 12,527 shares — an estimated $96.6K sold.

Diametric Capital first reported a position in VYGR in Q1 2023 and held it in 1 quarter. The position peaked at $96.6K in Q1 2023. 106 funds tracked by Wall St. Rank hold VYGR as of Q2 2023.

  • Diametric Capital reported no remaining Voyager Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Diametric Capital sold 12,527 Voyager Therapeutics shares in Q2 2023, an estimated $96.6K.
  • Diametric Capital first reported a position in Voyager Therapeutics in Q1 2023 and held it in 1 quarter.
  • Diametric Capital's Voyager Therapeutics position peaked at $96.6K in Q1 2023.
  • 106 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2023.

Based on Diametric Capital's 13F filing for Q2 2023, filed 11 Aug 2023.